Pharmaceutical Trials in Xinjiang Raise Regulatory Concerns
The pharmaceutical industry continues to conduct clinical trials in Xinjiang and at PLA hospitals, circumventing U.S. sanctions aimed at forced labor. This raises significant ethical concerns, particularly regarding human rights violations reported in the region.
Theia Market Signal Identification - AI Assisted
Multinational pharmaceutical companies have conducted numerous clinical trials in Xinjiang and at People's Liberation Army-affiliated sites, with AstraZeneca's Evusheld trial exemplifying this trend. Despite U.S. sanctions that apply to other sectors, drug manufacturers are exempt under the Uyghur Forced Labor Prevention Act, allowing them to operate without stringent oversight.
The House of Representatives' Select Committee on the Chinese Communist Party has called for increased scrutiny of these trials, highlighting potential human rights abuses. Current FDA regulations permit investigations, yet inquiries about trial oversight in Xinjiang remain unaddressed. The opacity of these operations poses risks to ethical standards in clinical research.
Comments